Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Parkinson's Disease

Free Subscription Articles published in Exp Neurol Retrieve available abstracts of 70 articles: HTML format

Single Articles

December 2025
1. KILPELAINEN T, Yang R, Toivio J, Etelainen T, et al
   Novel PREP ligand, HUP-46, ameliorates behavioral deficits in an alpha-synuclein based Parkinson's disease model.
   Exp Neurol. 2025 Dec 10:115593. doi: 10.1016/j.expneurol.2025.115593.
   PubMed     Abstract available
   
   
   
2. LIU R, Wang R, Zhou X, Chu F, et al
   Noninvasive deep brain stimulation using theta-burst transcranial magnetic-acoustic coupling to modulate cortical rhythms in Parkinsonian mice.
   Exp Neurol. 2025;397:115592.
   PubMed     Abstract available
   
   
   November 2025
3. SABOURIN S, Modi K, Williams J, Singh R, et al
   Levodopa differentially modulates spectral features in cerebellum and basal ganglia in a rodent model of Parkinson's disease.
   Exp Neurol. 2025;397:115579.
   PubMed     Abstract available
   
   
   
4. RUIZ MCM, Goulart JT, Dos Santos Penha G, de Santana IA, et al
   Early deep brain stimulation attenuates parkinsonism progression in a neurotoxin-induced Parkinson's disease mouse model.
   Exp Neurol. 2025 Nov 22:115567. doi: 10.1016/j.expneurol.2025.115567.
   PubMed     Abstract available
   
   
   
5. ELGHAREEB MM, Elshopakey GE, Rezk S, Ateya A, et al
   Platelet-rich plasma intervention as a therapeutic agent versus L-DOPA in Parkinson's model induced by rotenone in male albino rats.
   Exp Neurol. 2025 Nov 8:115545. doi: 10.1016/j.expneurol.2025.115545.
   PubMed     Abstract available
   
   
   October 2025
6. NAIDJI C, Katrib C, Devos D, Durieux N, et al
   Histo-radiological correlations in an early-stage model of a Parkinson's disease.
   Exp Neurol. 2025 Oct 29:115538. doi: 10.1016/j.expneurol.2025.115538.
   PubMed     Abstract available
   
   
   
7. SUN W, Wei J, Lin Z, Jiang C, et al
   An involvement of ribonuclease L in Parkinson's disease via modulating the Th17/Treg balance by microRNA-7.
   Exp Neurol. 2025;396:115517.
   PubMed     Abstract available
   
   
   
8. ISHII A, Meredith JR, Corenblum MJ, Bernard K, et al
   Lasmiditan ameliorates cortico-hippocampal pathology and improves cognition in aging parkinsonian mice.
   Exp Neurol. 2025 Oct 12:115502. doi: 10.1016/j.expneurol.2025.115502.
   PubMed     Abstract available
   
   
   
9. XU N, Du C, Yu Y, Li Y, et al
   Corrigendum to "Urolithin A improves Parkinson's disease-associated cognitive impairment through modulation of neuroinflammation and neuroplasticity" [Experiment neurology, 2025 Nov:393:115395, Manuscript ID during submission is EXNR-25-789, The proof
   Exp Neurol. 2025 Oct 10:115484. doi: 10.1016/j.expneurol.2025.115484.
   PubMed    
   
   
   
10. VENKATESH S, Kinzonzi N, Galfano A, Shah A, et al
    Optimizing L-DOPA treatment through treadmill controlled exercise in a hemi-parkinsonian rat model.
    Exp Neurol. 2025 Oct 8:115497. doi: 10.1016/j.expneurol.2025.115497.
    PubMed     Abstract available
    
    
    
11. MOLLER M, Nieweler JA, Nikulin VV, van Riesen C, et al
    Network mechanisms in rapid-onset dystonia-parkinsonism.
    Exp Neurol. 2025;395:115491.
    PubMed     Abstract available
    
    
    September 2025
12. BERTASINI C, Rossini M, Grisotto J, Emerich D, et al
    Gene therapy device-based delivery of progranulin, prosaposin, and GDNF as a combined precision and neurorestorative therapy in the rat 6-OHDA model of parkinsonism.
    Exp Neurol. 2025;395:115474.
    PubMed     Abstract available
    
    
    August 2025
13. WU X, Hui Y, Wang L, Qiao H, et al
    Long-term intermittent theta burst stimulation alleviates Parkinson's disease-related cognitive impairment by modulating GluN2B in the dorsal hippocampus.
    Exp Neurol. 2025;394:115439.
    PubMed     Abstract available
    
    
    
14. MIN X, Du Z, Wei J, Yuan Z, et al
    Corrigendum to "Pyridoxal Phosphate inhibits alpha-synuclein-induced ferroptosis by activating GOT1 to enhance the methionine salvage pathway in Parkinson's Disease" [Experimental Neurology (2025) 115411].
    Exp Neurol. 2025 Aug 20:115429. doi: 10.1016/j.expneurol.2025.115429.
    PubMed    
    
    
    
15. LU X, Qi Y, Xue J, Tang X, et al
    Chemogenetic activation of VTA neurons induces anxiety-like behavior in a Parkinson's disease model.
    Exp Neurol. 2025 Aug 12:115425. doi: 10.1016/j.expneurol.2025.115425.
    PubMed     Abstract available
    
    
    
16. MIN X, Du Z, Wei J, Yuan Z, et al
    Pyridoxal phosphate inhibits alpha-synuclein-induced ferroptosis by activating GOT1 to enhance the methionine salvage pathway in Parkinson's disease.
    Exp Neurol. 2025;393:115411.
    PubMed     Abstract available
    
    
    July 2025
17. XU N, Du C, Yu Y, Li Y, et al
    Urolithin a improves Parkinson's disease-associated cognitive impairment through modulation of neuroinflammation and neuroplasticity.
    Exp Neurol. 2025 Jul 24:115395. doi: 10.1016/j.expneurol.2025.115395.
    PubMed     Abstract available
    
    
    
18. LIU Y, Wang R, Sun F, Wang N, et al
    Stereotactic infusion of rotenone into the SN induced a late-stage model of Parkinson's disease.
    Exp Neurol. 2025 Jul 20:115382. doi: 10.1016/j.expneurol.2025.115382.
    PubMed     Abstract available
    
    
    
19. SINGH AA, Pathak Z, Chawathe A, Chopra M, et al
    High fat diet and low dose-rotenone exposure exacerbate Parkinson's disease like pathology through gut-brain axis disruption.
    Exp Neurol. 2025 Jul 19:115384. doi: 10.1016/j.expneurol.2025.115384.
    PubMed     Abstract available
    
    
    
20. MORISE S, Tohge R, Oki M, Takenouchi N, et al
    Zonisamide modulates cholinergic markers and alleviates levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Exp Neurol. 2025;393:115383.
    PubMed     Abstract available
    
    
    June 2025
21. KOC HI, Dogan E, Yelkenci HE, Bayraktaroglu C, et al
    Circadian rhythm disruption exacerbates neurodegeneration and alters proteomic profiles in a 6-OHDA induced Parkinson's disease model.
    Exp Neurol. 2025 Jun 23:115356. doi: 10.1016/j.expneurol.2025.115356.
    PubMed     Abstract available
    
    
    
22. XU Y, Zhang S, Mi J, Lu X, et al
    Modulatory effects of transcranial magneto-acoustic stimulation on behavior and corticostriatal transmission of oscillatory activity in a mouse model of Parkinson's disease induced by MPTP.
    Exp Neurol. 2025;392:115352.
    PubMed     Abstract available
    
    
    May 2025
23. ZIKEREYA T, Liu C, Wei L, Wang Y, et al
    The cannabinoid receptor 1 mediates exercise-induced improvements of motor skill learning and performance in parkinsonian mouse.
    Exp Neurol. 2025 May 6:115289. doi: 10.1016/j.expneurol.2025.115289.
    PubMed     Abstract available
    
    
    
24. PENG Y, Jiang DY, Yao SY, Zhang X, et al
    Gene-modified animal models of Parkinson's disease.
    Exp Neurol. 2025;390:115287.
    PubMed     Abstract available
    
    
    
25. MA J, Yang Y, Zang C, Chen Q, et al
    Inhibiting mitochondrial excessive fission alleviates the neuronal damage in Parkinson's disease via regulating PGC-1alpha mediated mitochondrial biogenesis.
    Exp Neurol. 2025 May 2:115288. doi: 10.1016/j.expneurol.2025.115288.
    PubMed     Abstract available
    
    
    April 2025
26. HONG JY, Lee JS, Kim SH, Lee PH, et al
    A model of L-DOPA-induced dyskinesia in parkinsonian mice produced by AAV vector-mediated overexpression of alpha-synuclein.
    Exp Neurol. 2025;389:115264.
    PubMed     Abstract available
    
    
    
27. ZHANG Y, Liang C, Weng M, Zhang Z, et al
    Intestinal alterations of mucosal barrier integrity, motility and enteric nerve in cynomolgus monkey model of Parkinson's disease.
    Exp Neurol. 2025;389:115256.
    PubMed     Abstract available
    
    
    
28. FENG N, Huang X, Jia Y
    Small extracellular vesicles from adipose derived stem cells alleviate microglia activation and improve motor deficit of Parkinson's disease via mir-100-5p/DTX3L/STAT1 signal axis.
    Exp Neurol. 2025 Apr 5:115250. doi: 10.1016/j.expneurol.2025.115250.
    PubMed     Abstract available
    
    
    
29. ZHANG L, Yan J, Song S, Yang Y, et al
    Detection of anxiety and depression-like behavior and intra-brain pathological markers in Parkinsonian cynomolgus monkeys.
    Exp Neurol. 2025;389:115242.
    PubMed     Abstract available
    
    
    March 2025
30. GAO Y, Liu W, Shi L, Yang P, et al
    Narirutin reduces microglia-mediated neuroinflammation by inhibiting the JAK2/STAT3 pathway in MPP(+)/MPTP-induced Parkinson's disease models.
    Exp Neurol. 2025;389:115232.
    PubMed     Abstract available
    
    
    February 2025
31. MIRANDA NC, Aquino YC, Macedo TO, Oliveira LM, et al
    Role of substantia Nigra dopaminergic neurons in respiratory modulation and limitations of levodopa in Parkinson's disease.
    Exp Neurol. 2025;387:115193.
    PubMed     Abstract available
    
    
    January 2025
32. LIANG JY, Yuan XL, Jiang JM, Zhang P, et al
    Targeting the NLRP3 inflammasome in Parkinson's disease: From molecular mechanism to therapeutic strategy.
    Exp Neurol. 2025 Jan 28:115167. doi: 10.1016/j.expneurol.2025.115167.
    PubMed     Abstract available
    
    
    
33. LIU T, Wu H, Wei J
    Molecular insights into Parkinson's disease and type 2 diabetes mellitus: Metformin's role and genetic pathways explored.
    Exp Neurol. 2025;385:115137.
    PubMed     Abstract available
    
    
    
34. QIAO CM, Ma XY, Tan LL, Xia YM, et al
    Indoleamine 2, 3-dioxygenase 1 inhibition mediates the therapeutic effects in Parkinson's disease mice by modulating inflammation and neurogenesis in a gut microbiota dependent manner.
    Exp Neurol. 2025 Jan 8:115142. doi: 10.1016/j.expneurol.2025.115142.
    PubMed     Abstract available
    
    
    December 2024
35. MONNOT C, Kalomoiri M, MacNicol E, Kim E, et al
    Early alterations of functional connectivity, regional brain volumes and astrocyte markers in the beta-sitosterol beta-d-glucoside (BSSG) rat model of parkinsonism.
    Exp Neurol. 2024 Dec 21:115118. doi: 10.1016/j.expneurol.2024.115118.
    PubMed     Abstract available
    
    
    
36. HUANG XL, Hu Y, Jiang W, Jiang JM, et al
    Suppression of cGAS/STING pathway-triggered necroptosis in the hippocampus relates H(2)S to attenuate cognitive dysfunction of Parkinson's disease.
    Exp Neurol. 2024 Dec 3:115093. doi: 10.1016/j.expneurol.2024.115093.
    PubMed     Abstract available
    
    
    
37. WANG H, Wu S, Jiang X, Li W, et al
    Acteoside alleviates salsolinol-induced Parkinson's disease by inhibiting ferroptosis via activating Nrf2/SLC7A11/GPX4 pathway.
    Exp Neurol. 2024 Dec 2:115084. doi: 10.1016/j.expneurol.2024.115084.
    PubMed     Abstract available
    
    
    
38. DAADI MM, Snyder EY
    Exercise your graft - An important lesson for cell replacement therapy for Parkinson's disease.
    Exp Neurol. 2024 Dec 2:115085. doi: 10.1016/j.expneurol.2024.115085.
    PubMed     Abstract available
    
    
    November 2024
39. NAKAMURA K
    Editorial: Intersection of neural activity, synuclein and Parkinson's disease.
    Exp Neurol. 2024 Nov 30:115091. doi: 10.1016/j.expneurol.2024.115091.
    PubMed    
    
    
    
40. SERRA M, Faustini G, Brembati V, Casu MA, et al
    Early alpha-synuclein/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease.
    Exp Neurol. 2024 Nov 3:115040. doi: 10.1016/j.expneurol.2024.115040.
    PubMed     Abstract available
    
    
    October 2024
41. LI Z, Luo J, Li C, Zhu H, et al
    Upregulation of Nav1.6 expression in the ventral posterolateral nucleus of thalamus contributes to hyperalgesia in a model of Parkinson's disease.
    Exp Neurol. 2024 Oct 25:115032. doi: 10.1016/j.expneurol.2024.115032.
    PubMed     Abstract available
    
    
    
42. ZHONG J, Yu X, Zhong Y, Tan L, et al
    GSK-3beta inhibitor amplifies autophagy-lysosomal pathways by regulating TFEB in Parkinson's disease models.
    Exp Neurol. 2024 Oct 25:115033. doi: 10.1016/j.expneurol.2024.115033.
    PubMed     Abstract available
    
    
    
43. SHI Y, Zhang J, Xiu M, Xie R, et al
    The zona incerta system: Involvement in Parkinson's disease.
    Exp Neurol. 2024 Oct 9:114992. doi: 10.1016/j.expneurol.2024.114992.
    PubMed     Abstract available
    
    
    September 2024
44. PAREKH P, Serra M, Allaw M, Perra M, et al
    Extract from Nasco pomace loaded in nutriosomes exerts anti-inflammatory effects in the MPTP mouse model of Parkinson's disease.
    Exp Neurol. 2024 Sep 18:114958. doi: 10.1016/j.expneurol.2024.114958.
    PubMed     Abstract available
    
    
    August 2024
45. BERNARD K, Mota JA, Wene P, Corenblum MJ, et al
    The angiotensin (1-7) glycopeptide PNA5 improvescognition in achronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation.
    Exp Neurol. 2024 Aug 15:114926. doi: 10.1016/j.expneurol.2024.114926.
    PubMed     Abstract available
    
    
    
46. NACCARATO MC, Oliveira LM, Ferreira CB, Moreira TS, et al
    Nucleus of the solitary tract neuronal degeneration and impaired hypoxia response in a model of Parkinson's disease.
    Exp Neurol. 2024 Aug 13:114924. doi: 10.1016/j.expneurol.2024.114924.
    PubMed     Abstract available
    
    
    July 2024
47. SAGREDO GT, Tanglay O, Shahdadpuri S, Fu Y, et al
    ?-Synuclein levels in Parkinson's disease - Cell types and forms that contribute to pathogenesis.
    Exp Neurol. 2024;379:114887.
    PubMed     Abstract available
    
    
    June 2024
48. KASANGA EA, Soto I, Centner A, McManus R, et al
    Moderate intensity aerobic exercise alleviates motor deficits in 6-OHDA lesioned rats and reduces serum levels of biomarkers of Parkinson's disease severity without recovery of striatal dopamine or tyrosine hydroxylase.
    Exp Neurol. 2024;379:114875.
    PubMed     Abstract available
    
    
    
49. LEI J, Tang LL, Jing R, You HJ, et al
    Antinociceptive role of the thalamic dopamine D3 receptor in descending modulation of intramuscular formalin-induced muscle nociception in a rat model of Parkinson's disease.
    Exp Neurol. 2024 Jun 13:114846. doi: 10.1016/j.expneurol.2024.114846.
    PubMed     Abstract available
    
    
    April 2024
50. FERREIRA AFF, Ulrich H, Feng ZP, Sun HS, et al
    Neurodegeneration and glial morphological changes are both prevented by TRPM2 inhibition during the progression of a Parkinson's disease mouse model.
    Exp Neurol. 2024;377:114780.
    PubMed     Abstract available
    
    
    March 2024
51. RUNWAL GM, Edwards RH
    The role of alpha-synuclein in exocytosis.
    Exp Neurol. 2024;373:114668.
    PubMed     Abstract available
    
    
    February 2024
52. JACQUES WJ, Estelle M, Samuel G, Belkacem M, et al
    State-dependent alteration of respiration in a rat model of Parkinson's disease.
    Exp Neurol. 2024 Feb 21:114740. doi: 10.1016/j.expneurol.2024.114740.
    PubMed     Abstract available
    
    
    
53. FU X, Qu L, Xu H, Xie J, et al
    Ndfip1 protected dopaminergic neurons via regulating mitochondrial function and ferroptosis in Parkinson's disease.
    Exp Neurol. 2024;375:114724.
    PubMed     Abstract available
    
    
    January 2024
54. MAZZOCCO MT, Serra M, Maspero M, Coliva A, et al
    Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson's disease.
    Exp Neurol. 2024 Jan 26:114704. doi: 10.1016/j.expneurol.2024.114704.
    PubMed     Abstract available
    
    
    
55. DAADI EW, Daadi ES, Oh T, Li M, et al
    Combining physical & cognitive training with iPSC-derived dopaminergic neuron transplantation promotes graft integration & better functional outcome in parkinsonian marmosets.
    Exp Neurol. 2024 Jan 23:114694. doi: 10.1016/j.expneurol.2024.114694.
    PubMed     Abstract available
    
    
    
56. SEILER JL, Zhuang X, Nelson AB, Lerner TN, et al
    Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression.
    Exp Neurol. 2024;374:114693.
    PubMed     Abstract available
    
    
    
57. ESER P, Kocabicak E, Bekar A, Temel Y, et al
    Insights into neuroinflammatory mechanisms of deep brain stimulation in Parkinson's disease.
    Exp Neurol. 2024 Jan 8:114684. doi: 10.1016/j.expneurol.2024.114684.
    PubMed     Abstract available
    
    
    December 2023
58. CORSI S, Scheggi S, Pardu A, Braccagni G, et al
    Corrigendum to "Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease" [Experimental neurology 2023 May;363:114370].
    Exp Neurol. 2023 Dec 15:114640. doi: 10.1016/j.expneurol.2023.114640.
    PubMed    
    
    
    
59. MANCHINU MF, Pala M, Palmas MF, Diana MA, et al
    Region-specific changes in gene expression are associated with cognitive deficits in the alpha-synuclein-induced model of Parkinson's disease: A transcriptomic profiling study.
    Exp Neurol. 2023 Dec 11:114651. doi: 10.1016/j.expneurol.2023.114651.
    PubMed     Abstract available
    
    
    
60. RADEMACHER K, Nakamura K
    Role of dopamine neuron activity in Parkinson's disease pathophysiology.
    Exp Neurol. 2023 Dec 11:114645. doi: 10.1016/j.expneurol.2023.114645.
    PubMed     Abstract available
    
    
    
61. ESER P, Kocabicak E, Bekar A, Temel Y, et al
    The interplay between neuroinflammatory pathways and Parkinson's disease.
    Exp Neurol. 2023 Dec 5:114644. doi: 10.1016/j.expneurol.2023.114644.
    PubMed     Abstract available
    
    
    
62. NIU B, Zhao M, Gao X, Xu J, et al
    TMT-based quantitative proteomics analysis of neuroprotective effects of Forsythoside A on the MPTP-induced Parkinson's disease mouse model.
    Exp Neurol. 2023 Dec 4:114642. doi: 10.1016/j.expneurol.2023.114642.
    PubMed     Abstract available
    
    
    November 2023
63. XIAO Z, Wang X, Pan X, Xie J, et al
    Mitochondrial iron dyshomeostasis and its potential as a therapeutic target for Parkinson's disease.
    Exp Neurol. 2023;372:114614.
    PubMed     Abstract available
    
    
    October 2023
64. BARCOMB K, Ford CP
    Alterations in neurotransmitter co-release in Parkinson's disease.
    Exp Neurol. 2023;370:114562.
    PubMed     Abstract available
    
    
    August 2023
65. KASANGA EA, Han Y, Shifflet MK, Navarrete W, et al
    Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs.
    Exp Neurol. 2023;368:114509.
    PubMed     Abstract available
    
    
    
66. KASANGA EA, Han Y, Navarrete W, McManus R, et al
    Differential expression of RET and GDNF family receptor, GFR-alpha1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling.
    Exp Neurol. 2023;366:114435.
    PubMed     Abstract available
    
    
    June 2023
67. LIU Y, Liu H, Lu Y, Yin X, et al
    Non-invasive auditory and visual stimulation attenuates alpha-Synuclein deposition and improves motor and non-motor symptoms in PD mice.
    Exp Neurol. 2023;364:114396.
    PubMed     Abstract available
    
    
    May 2023
68. HART M, Conrad J, Barrett E, Legg K, et al
    X-linked hydrocephalus genes: Their proximity to telomeres and high a + T content compared to Parkinson's disease.
    Exp Neurol. 2023 May 6:114433. doi: 10.1016/j.expneurol.2023.114433.
    PubMed     Abstract available
    
    
    April 2023
69. RIVAS-SANTISTEBAN R, Lillo J, Raich I, Munoz A, et al
    The cannabinoid CB(1) receptor interacts with the angiotensin AT(2) receptor. Overexpression of AT(2)-CB(1) receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats.
    Exp Neurol. 2023;362:114319.
    PubMed     Abstract available
    
    
    March 2023
70. SARA C, Simona S, Alessandra P, Giulia B, et al
    Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Exp Neurol. 2023 Mar 4:114370. doi: 10.1016/j.expneurol.2023.114370.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.